TD-6450

DRUG4 trials

Sponsors

Theravance Biopharma, Trek Therapeutics, PBC

Conditions

Chronic Hepatitis CHCVHepatitis CHepatitis C (HCV)Hepatitis C Genotype 1Hepatitis C Genotype 4Hepatitis C Viral Infection

Phase 1

TD-6450 SAD and MAD in Healthy Subjects

CompletedNCT02022306

Theravance BiopharmaHepatitis C

Start: 2014-02-28End: 2014-09-30Updated: 2021-01-14

TD-6450 MAD Study in HCV Infected Subjects

CompletedNCT02116543

Theravance BiopharmaHCV, Hepatitis C

Start: 2014-05-31End: 2014-11-30Updated: 2021-01-19

Phase 2

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

CompletedNCT02593162

Trek Therapeutics, PBCChronic Hepatitis C, Hepatitis C Genotype 4, Hepatitis C (HCV) +1

Start: 2015-10-31End: 2016-12-31Updated: 2017-01-30

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

CompletedNCT02716428

Trek Therapeutics, PBCChronic Hepatitis C, Hepatitis C Genotype 1, Hepatitis C (HCV) +1

Start: 2016-05-31End: 2017-09-30Updated: 2017-10-17

Related Papers

Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening.

2023-04-0710 citations

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment

PLoS ONE2016-12-285 citations